Shots:
- AstraZeneca has reported interim P-III (TULIP-SC) trial data assessing Saphnelo (anifrolumab; 120mg, SC, QW, accessorisedPFS) vs PBO in 367 pts (18-70yrs.) with mod. to sev. active, autoantibody-positive SLE while receiving SoC
- Interim analysis conducted after the first 220 pts reached Wk. 52, showed Saphnelo reduced disease activity (1EP), measured by BICLA at Wk. 52; data to be presented at ACR’25 & is under regulatory review
- Additionally, AstraZeneca gained global rights to Saphnelo through an exclusive license agreement in 2004 with Medarex, whose co-promotion option lapsed upon its 2009 acquisition by BMS, & will pay BMS low to mid-teens sales royalties based on geography
Ref: AstraZeneca | Image: AstraZeneca | Press Release
Related News:- AstraZeneca Reports P-III (FLAURA2) Trial Findings on Tagrisso Regimen to Treat EGFRm NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
